PMID- 10233741
OWN - NLM
STAT- MEDLINE
DCOM- 19990730
LR  - 20190513
IS  - 0019-2805 (Print)
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Linking)
VI  - 96
IP  - 4
DP  - 1999 Apr
TI  - Inhibition of mast cell-dependent anaphylaxis by sodium salicylate.
PG  - 551-6
AB  - Sodium salicylate (NaSal) is a commonly used agent with a wide pharmacological 
      spectrum. The objective of the present study was to investigate the effect of 
      NaSal on anaphylaxis. NaSal (10-1 and 1 mm) significantly inhibited systemic 
      anaphylaxis induced by compound 48/80 in rats. NaSal also significantly inhibited 
      local anaphylaxis activated by anti-dinitrophenyl (DNP) immunoglobulin E (IgE). 
      NaSal (10-1 and 1 mm) significantly inhibited histamine release from rat 
      peritoneal mast cells (RPMC) activated by compound 48/80 or anti-DNP IgE. 
      Northern-blot analysis demonstrated that a significantly reduced level of the 
      mRNA of L-histidine decarboxylase was expressed in mast cells treated with NaSal, 
      compared with that without NaSal. NaSal (10-2 and 10-1 mm) had a significant 
      inhibitory effect on anti-DNP IgE-induced tumour necrosis factor-alpha secretion 
      from RPMC. The level of cyclic AMP in RPMC, when NaSal (1 mm) was added, 
      transiently and significantly increased about sixfold compared with that of basal 
      cells. These results suggest a possible use of NaSal in managing mast 
      cell-dependent anaphylaxis.
FAU - Kim, H M
AU  - Kim HM
AD  - Department of Oriental Pharmacy, College of Pharmacy, Division of Biological 
      Science, College of Natural Sciences, Wonkwang University, Iksan, South Korea.
FAU - Shin, H Y
AU  - Shin HY
FAU - Choo, Y K
AU  - Choo YK
FAU - Park, J K
AU  - Park JK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 33507-63-0 (Substance P)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 4091-50-3 (p-Methoxy-N-methylphenethylamine)
RN  - E0399OZS9N (Cyclic AMP)
RN  - EC 4.1.1.22 (Histidine Decarboxylase)
RN  - WIQ1H85SYP (Sodium Salicylate)
SB  - IM
MH  - Anaphylaxis/*prevention & control
MH  - Animals
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Cyclic AMP/metabolism
MH  - Gene Expression
MH  - Histamine Release/drug effects
MH  - Histidine Decarboxylase/biosynthesis/genetics
MH  - Immunoglobulin E/immunology
MH  - Mast Cells/*drug effects/immunology
MH  - Passive Cutaneous Anaphylaxis/immunology
MH  - RNA, Messenger/genetics
MH  - Rats
MH  - Rats, Wistar
MH  - Sodium Salicylate/*therapeutic use
MH  - Substance P/pharmacology
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - p-Methoxy-N-methylphenethylamine
PMC - PMC2326792
EDAT- 1999/05/08 00:00
MHDA- 1999/05/08 00:01
PMCR- 2000/04/01
CRDT- 1999/05/08 00:00
PHST- 1999/05/08 00:00 [pubmed]
PHST- 1999/05/08 00:01 [medline]
PHST- 1999/05/08 00:00 [entrez]
PHST- 2000/04/01 00:00 [pmc-release]
AID - imm729 [pii]
AID - 10.1046/j.1365-2567.1999.00729.x [doi]
PST - ppublish
SO  - Immunology. 1999 Apr;96(4):551-6. doi: 10.1046/j.1365-2567.1999.00729.x.